Raphael Miller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Raphael Miller has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- David Joseph Altschul
Department of Neurosurgery, Montefiore Medical Center, Bronx, New York, USA
4 shared publications - Santiago René Unda
Department of Neurological Surgery Weill Cornell Medical College 10065 New York NY
4 shared publications - Daniel M. Klyde
Albert Einstein College of Medicine, Bronx, NY 10461***, USA
3 shared publications - Aldana M. Antoniazzi
Laboratory of Molecular Neurosurgery, Department of Neurological Surgery, Weill Cornell Medical College, Cornell University; New York, NY, USA
2 shared publications Rose Fluss
Montefiore Medical Center, Bronx, NY 10467, USA
2 shared publicationsAnna Tarasova
1 shared publication
Latest Publications
- Open Access
- 31 August 2026
- Published by Elsevier in Radiology Case Reports
- Vol. 21 (11) , 5715-5718
Imaging findings of an obturator hernia: A rare cause of small bowel obstruction
- 31 August 2026
- Published by Elsevier in Radiology Case Reports
- Vol. 21 (11) , 5715-5718
Open AccessImaging findings of an obturator hernia: A rare cause of small bowel obstruction
- Open Access
- 7 October 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 17 (12) , 4828-4833
Malignant solitary fibrous tumor of the floor of the mouth in a 71-year-old male: A case report
- 7 October 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 17 (12) , 4828-4833
Open AccessMalignant solitary fibrous tumor of the floor of the mouth in a 71-year-old male: A case report
- Open Access
- 15 September 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 17 (11) , 4341-4344
Case report: Use of unenhanced cardiac MR to evaluate low flow states for thrombus
- 15 September 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 17 (11) , 4341-4344
Open AccessCase report: Use of unenhanced cardiac MR to evaluate low flow states for thrombus
- 1 December 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (12) , 106089
Classical Risk Factors for Ischemic Stroke are not Associated with Inpatient Post-Stroke Mortality in Sickle Cell Disease
- 1 December 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (12) , 106089
Classical Risk Factors for Ischemic Stroke are not Associated with Inpatient Post-Stroke Mortality in Sickle Cell Disease
- Open Access
- 22 November 2021
- Published by Springer Nature in Cureus
- Vol. 13 (11) , e19812
Western Moyamoya Phenotype: A Scoping Review
Moyamoya, a rare angiographic finding, is characterized by chronic and progressive stenosis at the terminal end of the internal carotid artery, followed by collateralization of the cerebral vasculature at the base of the skull. Coined by Suzuki and Takaku in 1969, the term “moyamoya” means a “puff of smoke” in Japanese, a reference to the angiographic appearance of moyamoya collateralization. Moyamoya is most commonly found in East Asian countries, where much governmental and civilian effort has been expended to characterize this unique disease process. However, despite its rarity, the occurrence of moyamoya in Western countries is associated with significant divergence regarding incidence, gender, sex, age at diagnosis, clinical presentation, and outcomes. Here, we attempted to review the Western literature on moyamoya presentation using the PubMed database to characterize the Western phenotype of moyamoya. We were guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews (PRISMA-ScR). We reviewed papers generated from a search with keywords “moyamoya case report,” those reported from a Western institution, and those reported on a relevant association. Our scoping review demonstrated various clinical associations with moyamoya. Moreover, we summarized the demographic profile and clinical symptomatology, as well as reported disease associations to better elucidate the Western phenotype of moyamoya.
- 22 November 2021
- Published by Springer Nature in Cureus
- Vol. 13 (11) , e19812
Open AccessWestern Moyamoya Phenotype: A Scoping Review
Moyamoya, a rare angiographic finding, is characterized by chronic and progressive stenosis at the terminal end of the internal carotid artery, followed by collateralization of the cerebral vasculature at the base of the skull. Coined by Suzuki and Takaku in 1969, the term “moyamoya” means a “puff of smoke” in Japanese, a reference to the angiographic appearance of moyamoya collateralization. Moyamoya is most commonly found in East Asian countries, where much governmental and civilian effort has been expended to characterize this unique disease process. However, despite its rarity, the occurrence of moyamoya in Western countries is associated with significant divergence regarding incidence, gender, sex, age at diagnosis, clinical presentation, and outcomes. Here, we attempted to review the Western literature on moyamoya presentation using the PubMed database to characterize the Western phenotype of moyamoya. We were guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews (PRISMA-ScR). We reviewed papers generated from a search with keywords “moyamoya case report,” those reported from a Western institution, and those reported on a relevant association. Our scoping review demonstrated various clinical associations with moyamoya. Moreover, we summarized the demographic profile and clinical symptomatology, as well as reported disease associations to better elucidate the Western phenotype of moyamoya.
- 1 September 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (9) , 105965
Moyamoya Disease and Syndrome: A National Inpatient Study of Ischemic Stroke Predictors
- 1 September 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (9) , 105965
Moyamoya Disease and Syndrome: A National Inpatient Study of Ischemic Stroke Predictors
- Open Access
- 11 May 2021
- Published by Springer Nature in Cureus
- Vol. 13 (5)
Sterile Leukocytosis Predicts Hemorrhagic Transformation in Arterial Ischemic Stroke: A National Inpatient Sample Study
Objective: Hemorrhage transformation (HT) is a known complication of arterial ischemic stroke (AIS). In addition, it is known that the increase of proinflammatory immune cells in the brain tissue after MS predict worse outcomes. However, it is not clear whether inflammation due to preceding or post-stroke infections affect outcomes and moreover, if systemic inflammatory markers could be useful as a clinical prediction tool for HT post-stroke. Therefore, our objective was to assess the association between systemic proinflammatory profile in AIS patients with HT and in-hospital mortality that did not course with acute infections during hospitalization. Methods: This study was conducted using the 2016 and 2017 National Inpatient Sample (NIS) with International Classification of Diseases (ICD-10) codes. Multivariate logistic regression was used to examine the association between HT and in-hospital mortality with pro-inflammatory anomalies of white blood cells (WBCs) in MS patients. Exclusion criteria comprised patients with under 18 years old, and with a diagnosis of gastrointestinal, urogenital, respiratory infection, bacteremia, viral infection, sepsis, or fever. Results: A total of 212,356 patients with MS were included in the analysis. 422 (0.2%) patients had a HT and 10,230 (4.8%) patients died during hospitalization. The most common WBC pro-inflammatory marker was leukocytosis with 6.9% (n=29/422) of HT and 5.5% (n=560/10,230) of patients that died during hospitalization. After adjusting for socio-demographic, comorbidities and treatment factors, leukocytosis was found to be an independent risk factor for both outcomes, HT [OR = 1.5, 95% CI: 1-2.3, p=0.024] and, in-hospital mortality [OR = 1.5, 95% CI: 1.3-1.6, p < 0.001]. Conclusion: Sterile leukocytosis is a potential clinical prediction tool to determine which patients are at higher risk of developing HT and die during hospitalization.
- 11 May 2021
- Published by Springer Nature in Cureus
- Vol. 13 (5)
Open AccessSterile Leukocytosis Predicts Hemorrhagic Transformation in Arterial Ischemic Stroke: A National Inpatient Sample Study
Objective: Hemorrhage transformation (HT) is a known complication of arterial ischemic stroke (AIS). In addition, it is known that the increase of proinflammatory immune cells in the brain tissue after MS predict worse outcomes. However, it is not clear whether inflammation due to preceding or post-stroke infections affect outcomes and moreover, if systemic inflammatory markers could be useful as a clinical prediction tool for HT post-stroke. Therefore, our objective was to assess the association between systemic proinflammatory profile in AIS patients with HT and in-hospital mortality that did not course with acute infections during hospitalization. Methods: This study was conducted using the 2016 and 2017 National Inpatient Sample (NIS) with International Classification of Diseases (ICD-10) codes. Multivariate logistic regression was used to examine the association between HT and in-hospital mortality with pro-inflammatory anomalies of white blood cells (WBCs) in MS patients. Exclusion criteria comprised patients with under 18 years old, and with a diagnosis of gastrointestinal, urogenital, respiratory infection, bacteremia, viral infection, sepsis, or fever. Results: A total of 212,356 patients with MS were included in the analysis. 422 (0.2%) patients had a HT and 10,230 (4.8%) patients died during hospitalization. The most common WBC pro-inflammatory marker was leukocytosis with 6.9% (n=29/422) of HT and 5.5% (n=560/10,230) of patients that died during hospitalization. After adjusting for socio-demographic, comorbidities and treatment factors, leukocytosis was found to be an independent risk factor for both outcomes, HT [OR = 1.5, 95% CI: 1-2.3, p=0.024] and, in-hospital mortality [OR = 1.5, 95% CI: 1.3-1.6, p < 0.001]. Conclusion: Sterile leukocytosis is a potential clinical prediction tool to determine which patients are at higher risk of developing HT and die during hospitalization.